Franchises et coassurance : Questions médicales fréquentes
Nom anglais: Deductibles and Coinsurance
Descriptor UI:D003669
Tree Number:N03.219.521.576.090.300
Termes MeSH sélectionnés :
Interleukin-1
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Franchises et coassurance : Questions médicales les plus fréquentes",
"headline": "Franchises et coassurance : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Franchises et coassurance : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-08",
"dateModified": "2025-04-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Franchises et coassurance"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Participation aux coûts",
"url": "https://questionsmedicales.fr/mesh/D017047",
"about": {
"@type": "MedicalCondition",
"name": "Participation aux coûts",
"code": {
"@type": "MedicalCode",
"code": "D017047",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.219.521.576.090"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Franchises et coassurance",
"alternateName": "Deductibles and Coinsurance",
"code": {
"@type": "MedicalCode",
"code": "D003669",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "J Frank Wharam",
"url": "https://questionsmedicales.fr/author/J%20Frank%20Wharam",
"affiliation": {
"@type": "Organization",
"name": "Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA."
}
},
{
"@type": "Person",
"name": "Alisa B Busch",
"url": "https://questionsmedicales.fr/author/Alisa%20B%20Busch",
"affiliation": {
"@type": "Organization",
"name": "Department of Health Care Policy, Harvard Medical School."
}
},
{
"@type": "Person",
"name": "Fang Zhang",
"url": "https://questionsmedicales.fr/author/Fang%20Zhang",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Dennis Ross-Degnan",
"url": "https://questionsmedicales.fr/author/Dennis%20Ross-Degnan",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Mark K Meiselbach",
"url": "https://questionsmedicales.fr/author/Mark%20K%20Meiselbach",
"affiliation": {
"@type": "Organization",
"name": "Health Policy and Management, Johns Hopkins University, Baltimore, Maryland, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Subdural Levels of Interleukin 1-receptor Antagonist are Elevated in Patients with Recurrent Chronic Subdural Hematomas.",
"datePublished": "2023-04-11",
"url": "https://questionsmedicales.fr/article/37039933",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10753-023-01811-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "\"How to Release or Not Release, That Is the Question.\" A Review of Interleukin-1 Cellular Release Mechanisms in Vascular Inflammation.",
"datePublished": "2024-02-23",
"url": "https://questionsmedicales.fr/article/38390810",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1161/JAHA.123.032987"
}
},
{
"@type": "ScholarlyArticle",
"name": "Serum interleukin-1 is a new biomarker to predict the risk of rebleeding of ruptured intracranial aneurysm after admission.",
"datePublished": "2023-05-17",
"url": "https://questionsmedicales.fr/article/37195327",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10143-023-02010-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of interleukin-1 antagonists on de novo and pre-existing damage in patients with familial Mediterranean fever.",
"datePublished": "2023-05-15",
"url": "https://questionsmedicales.fr/article/37199170",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.55563/clinexprheumatol/cbiyem"
}
},
{
"@type": "ScholarlyArticle",
"name": "The role of genetic polymorphisms of interleukin-1 (IL-1R1 and IL-1RN) in primary knee osteoarthritis in Indonesia.",
"datePublished": "2023-05-17",
"url": "https://questionsmedicales.fr/article/37198429",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-34824-2"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Organisations et économie des soins de santé",
"item": "https://questionsmedicales.fr/mesh/D004472"
},
{
"@type": "ListItem",
"position": 3,
"name": "Économie",
"item": "https://questionsmedicales.fr/mesh/D004467"
},
{
"@type": "ListItem",
"position": 4,
"name": "Financement organisé",
"item": "https://questionsmedicales.fr/mesh/D005381"
},
{
"@type": "ListItem",
"position": 5,
"name": "Assurance",
"item": "https://questionsmedicales.fr/mesh/D007341"
},
{
"@type": "ListItem",
"position": 6,
"name": "Participation aux coûts",
"item": "https://questionsmedicales.fr/mesh/D017047"
},
{
"@type": "ListItem",
"position": 7,
"name": "Franchises et coassurance",
"item": "https://questionsmedicales.fr/mesh/D003669"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Franchises et coassurance - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Franchises et coassurance",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Franchises et coassurance",
"description": "Qu'est-ce qu'une franchise en assurance santé ?\nComment fonctionne la coassurance ?\nQuelle est la différence entre franchise et coassurance ?\nComment sont calculées les franchises ?\nLes franchises sont-elles remboursables ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Interleukin-1&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Franchises et coassurance",
"description": "Quels sont les impacts d'une franchise élevée ?\nComment la coassurance affecte-t-elle les patients ?\nLes patients ressentent-ils du stress à cause des franchises ?\nLes franchises influencent-elles la santé des patients ?\nY a-t-il des symptômes financiers liés à la coassurance ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Interleukin-1&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Franchises et coassurance",
"description": "Comment éviter des frais élevés de franchise ?\nLes bilans de santé sont-ils couverts sans franchise ?\nComment éduquer les patients sur les franchises ?\nLes programmes de prévention réduisent-ils les coûts ?\nComment les patients peuvent-ils planifier leurs soins ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Interleukin-1&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Franchises et coassurance",
"description": "Comment choisir un plan avec franchise ?\nLes traitements préventifs sont-ils couverts ?\nComment réduire les coûts de coassurance ?\nLes médicaments sont-ils soumis à la franchise ?\nLes soins d'urgence sont-ils affectés par la coassurance ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Interleukin-1&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Franchises et coassurance",
"description": "Quelles complications peuvent survenir avec des franchises élevées ?\nLa coassurance peut-elle entraîner des complications financières ?\nLes patients évitent-ils des soins à cause des coûts ?\nComment les complications de santé affectent-elles les coûts ?\nLes complications dues à la coassurance sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Interleukin-1&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Franchises et coassurance",
"description": "Quels facteurs augmentent les coûts de franchise ?\nComment le choix de l'assurance affecte-t-il les coûts ?\nLes maladies chroniques augmentent-elles les frais ?\nLes jeunes adultes ont-ils des franchises plus basses ?\nLes habitudes de santé influencent-elles les coûts ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Interleukin-1&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Qu'est-ce qu'une franchise en assurance santé ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est le montant que le patient doit payer avant que l'assurance ne couvre les frais."
}
},
{
"@type": "Question",
"name": "Comment fonctionne la coassurance ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est le pourcentage des frais médicaux que le patient doit payer après la franchise."
}
},
{
"@type": "Question",
"name": "Quelle est la différence entre franchise et coassurance ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "La franchise est un montant fixe, tandis que la coassurance est un pourcentage des frais."
}
},
{
"@type": "Question",
"name": "Comment sont calculées les franchises ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont généralement fixées par le contrat d'assurance et varient selon les plans."
}
},
{
"@type": "Question",
"name": "Les franchises sont-elles remboursables ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les montants de franchise ne sont pas remboursés par l'assurance."
}
},
{
"@type": "Question",
"name": "Quels sont les impacts d'une franchise élevée ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une franchise élevée peut dissuader les patients de consulter des soins médicaux."
}
},
{
"@type": "Question",
"name": "Comment la coassurance affecte-t-elle les patients ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des coûts supplémentaires pour les patients lors de soins médicaux."
}
},
{
"@type": "Question",
"name": "Les patients ressentent-ils du stress à cause des franchises ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les coûts imprévus peuvent causer de l'anxiété financière chez les patients."
}
},
{
"@type": "Question",
"name": "Les franchises influencent-elles la santé des patients ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent limiter l'accès aux soins, affectant ainsi la santé globale des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes financiers liés à la coassurance ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des frais médicaux imprévus peuvent entraîner des difficultés financières."
}
},
{
"@type": "Question",
"name": "Comment éviter des frais élevés de franchise ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Choisissez un plan avec une franchise adaptée à vos besoins médicaux prévisibles."
}
},
{
"@type": "Question",
"name": "Les bilans de santé sont-ils couverts sans franchise ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, les bilans de santé préventifs sont couverts sans frais de franchise."
}
},
{
"@type": "Question",
"name": "Comment éduquer les patients sur les franchises ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fournissez des informations claires sur les coûts et les options d'assurance disponibles."
}
},
{
"@type": "Question",
"name": "Les programmes de prévention réduisent-ils les coûts ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent réduire les coûts à long terme en évitant des soins coûteux."
}
},
{
"@type": "Question",
"name": "Comment les patients peuvent-ils planifier leurs soins ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils doivent évaluer leurs besoins et choisir des soins en fonction de leur plan d'assurance."
}
},
{
"@type": "Question",
"name": "Comment choisir un plan avec franchise ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluez vos besoins médicaux et comparez les coûts des franchises et coassurances."
}
},
{
"@type": "Question",
"name": "Les traitements préventifs sont-ils couverts ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, les traitements préventifs sont couverts sans franchise, selon le plan."
}
},
{
"@type": "Question",
"name": "Comment réduire les coûts de coassurance ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Choisissez des soins dans le réseau de votre assurance pour réduire les frais."
}
},
{
"@type": "Question",
"name": "Les médicaments sont-ils soumis à la franchise ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent être soumis à la franchise selon le plan d'assurance."
}
},
{
"@type": "Question",
"name": "Les soins d'urgence sont-ils affectés par la coassurance ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les soins d'urgence peuvent entraîner des frais de coassurance après la franchise."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des franchises élevées ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients peuvent retarder des soins nécessaires, entraînant des complications de santé."
}
},
{
"@type": "Question",
"name": "La coassurance peut-elle entraîner des complications financières ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des frais imprévus peuvent causer des dettes médicales importantes."
}
},
{
"@type": "Question",
"name": "Les patients évitent-ils des soins à cause des coûts ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les coûts élevés peuvent dissuader les patients de rechercher des soins médicaux."
}
},
{
"@type": "Question",
"name": "Comment les complications de santé affectent-elles les coûts ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent entraîner des frais médicaux supplémentaires et imprévus."
}
},
{
"@type": "Question",
"name": "Les complications dues à la coassurance sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux patients rencontrent des difficultés à payer leurs frais médicaux."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent les coûts de franchise ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge, les antécédents médicaux et le type de soins peuvent influencer les coûts."
}
},
{
"@type": "Question",
"name": "Comment le choix de l'assurance affecte-t-il les coûts ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Différents plans d'assurance ont des franchises et coassurances variées, influençant les coûts."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques augmentent-elles les frais ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients avec des maladies chroniques peuvent faire face à des frais plus élevés."
}
},
{
"@type": "Question",
"name": "Les jeunes adultes ont-ils des franchises plus basses ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, les jeunes adultes choisissent des plans avec des franchises plus basses."
}
},
{
"@type": "Question",
"name": "Les habitudes de santé influencent-elles les coûts ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de santé positives peuvent réduire les frais médicaux à long terme."
}
}
]
}
]
}
Anti-inflammatory treatment reduces the risk of recurrent chronic subdural hematoma (CSDH), but clinical implementation is improper due to side effects. Exact knowledge of subdural molecules involved ...
Cardiovascular disease remains the leading cause of death worldwide, characterized by atherosclerotic activity within large and medium-sized arteries. Inflammation has been shown to be a primary drive...
Interleukin-1 (IL-1) could induce inflammation of the aneurysm wall, which might be related to intracranial aneurysm rupture. The aim of this study was to investigate whether IL-1 could serve as a bio...
Colchicine is the mainstay of familial Mediterranean fever treatment and interleukin (IL-1) antagonists are the treatment of choice in resistant patients. We aimed to investigate efficacy of IL-1 anta...
A total of 111 patients fulfilling Euro fever and Tel-Hashomer criteria and treated with IL-1 antagonists were included in the study. Patients were grouped according to their recent damage status: no ...
Forty-six patients (43,2 %) had damage according to the mADDI. Damage was commonly observed at musculoskeletal, renal and reproductive domains. Median duration of treatment was forty-five months. Two ...
We evaluated change in damage accrual while using IL-1 antagonists in patients with FMF. Physicians should pay attention to controlling inflammation to prevent further damage, especially in those with...
This study aimed to evaluate the association of SNPs of the IL-1 family with the clinical severity of knee OA. This case‒control study was performed among 100 healthy knees and 130 osteoarthritis (OA)...
Interleukin-1 (IL-1) blockade with anakinra given within 12 hours from reperfusion has been shown to reduce the inflammatory response as well as prevent heart failure (HF) events in patients with STEM...
While meant for wound healing and immunity in response to injury and infection, inflammatory signaling is usurped by cancerous tumors to promote disease progression, including treatment resistance. Th...
Cryopyrin-associated periodic syndromes (CAPS) are orphan hereditary auto-inflammatory diseases with various phenotypes, including chronic kidney disease (CKD). Current therapies inhibit interleukin-1...
Bronchopulmonary dysplasia (BPD), its complication pulmonary hypertension (BPD-PH) and preterm brain and gut injury lead to significant morbidity and mortality in infants born extremely prematurely. T...
Anakinra Pilot is an investigator-initiated, single arm, safety and feasibility dose-escalation trial in extremely preterm infants born between 24 weeks 0 days (24...
https://clinicaltrials.gov/, identifier NCT05280340....
Recombinant human interleukin-1 receptor antagonist (anakinra) is an anti-inflammatory with efficacy in animal models of stroke. We tested the effect of anakinra on perihaematomal oedema in acute intr...
We conducted a multicentre, randomised, double-blind, placebo-controlled trial in patients with acute, spontaneous, supratentorial ICH between May 2019 and February 2021. Patients were randomised to 1...
25 patients (target = 80) were recruited, 14 randomised to anakinra, 11 to placebo. Mean age was 67 and 52% were male. The anakinra group had higher median baseline ICH volume (12.6 ml, interquartile ...
We describe feasibility for delivering anakinra in acute ICH and provide preliminary safety data. We lacked power to test for effects on oedema thus further trials will be required....